169 related articles for article (PubMed ID: 38604813)
1. Autologous human preclinical modeling of melanoma interpatient clinical responses to immunotherapeutics.
Phoon YP; Lopes JE; Pfannenstiel LW; Marcela Diaz-Montero C; Tian YF; Ernstoff MS; Funchain P; Ko JS; Winquist R; Losey HC; Melenhorst JJ; Gastman BR
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38604813
[TBL] [Abstract][Full Text] [Related]
2. Promising preclinical platform for evaluation of immuno-oncology drugs using Hu-PBL-NSG lung cancer models.
Pyo KH; Kim JH; Lee JM; Kim SE; Cho JS; Lim SM; Cho BC
Lung Cancer; 2019 Jan; 127():112-121. PubMed ID: 30642538
[TBL] [Abstract][Full Text] [Related]
3. Nemvaleukin alfa, a novel engineered IL-2 fusion protein, drives antitumor immunity and inhibits tumor growth in small cell lung cancer.
Pan Y; Hao Y; Han H; Chen T; Ding H; Labbe KE; Shum E; Guidry K; Hu H; Sherman F; Geng K; Stephens J; Chafitz A; Tang S; Huang HY; Peng C; Almonte C; Lopes JE; Losey HC; Winquist RJ; Velcheti V; Zhang H; Wong KK
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36472839
[TBL] [Abstract][Full Text] [Related]
4. Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.
Ascierto PA; Agarwala S; Botti G; Cesano A; Ciliberto G; Davies MA; Demaria S; Dummer R; Eggermont AM; Ferrone S; Fu YX; Gajewski TF; Garbe C; Huber V; Khleif S; Krauthammer M; Lo RS; Masucci G; Palmieri G; Postow M; Puzanov I; Silk A; Spranger S; Stroncek DF; Tarhini A; Taube JM; Testori A; Wang E; Wargo JA; Yee C; Zarour H; Zitvogel L; Fox BA; Mozzillo N; Marincola FM; Thurin M
J Transl Med; 2016 Nov; 14(1):313. PubMed ID: 27846884
[TBL] [Abstract][Full Text] [Related]
5. Clinical responses to adoptive T-cell transfer can be modeled in an autologous immune-humanized mouse model.
Jespersen H; Lindberg MF; Donia M; Söderberg EMV; Andersen R; Keller U; Ny L; Svane IM; Nilsson LM; Nilsson JA
Nat Commun; 2017 Sep; 8(1):707. PubMed ID: 28955032
[TBL] [Abstract][Full Text] [Related]
6. ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy.
Lopes JE; Fisher JL; Flick HL; Wang C; Sun L; Ernstoff MS; Alvarez JC; Losey HC
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32317293
[TBL] [Abstract][Full Text] [Related]
7. Fine-tuned long-acting interleukin-2 superkine potentiates durable immune responses in mice and non-human primate.
Merchant R; Galligan C; Munegowda MA; Pearce LB; Lloyd P; Smith P; Merchant F; To MD
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35058325
[TBL] [Abstract][Full Text] [Related]
8. Combination of radiation therapy, bempegaldesleukin, and checkpoint blockade eradicates advanced solid tumors and metastases in mice.
Pieper AA; Rakhmilevich AL; Spiegelman DV; Patel RB; Birstler J; Jin WJ; Carlson PM; Charych DH; Hank JA; Erbe AK; Overwijk WW; Morris ZS; Sondel PM
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34172518
[TBL] [Abstract][Full Text] [Related]
9. Fidelity of human ovarian cancer patient-derived xenografts in a partially humanized mouse model for preclinical testing of immunotherapies.
Odunsi A; McGray AJR; Miliotto A; Zhang Y; Wang J; Abiola A; Eppolito C; Huang RY
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33177175
[TBL] [Abstract][Full Text] [Related]
10. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
[TBL] [Abstract][Full Text] [Related]
11. Establishment of humanized tumor microenvironment mouse models based on the injection of peripheral blood mononuclear cells and IFN-γ to evaluate the efficacy of PD-L1/PD-1-targeted immunotherapy.
Lin X; Zeng T; Lin J; Zhang Q; Cheng H; Fang S; Lin S; Chen Y; Xu Y; Lin J
Cancer Biol Ther; 2020; 21(2):130-138. PubMed ID: 31690181
[TBL] [Abstract][Full Text] [Related]
12. Rethinking Oncologic Treatment Strategies with Interleukin-2.
Ko B; Takebe N; Andrews O; Makena MR; Chen AP
Cells; 2023 May; 12(9):. PubMed ID: 37174716
[TBL] [Abstract][Full Text] [Related]
13. Human melanoma immunotherapy using tumor antigen-specific T cells generated in humanized mice.
Hu Z; Xia J; Fan W; Wargo J; Yang YG
Oncotarget; 2016 Feb; 7(6):6448-59. PubMed ID: 26824989
[TBL] [Abstract][Full Text] [Related]
14. Tumor specific cytolysis by tumor infiltrating lymphocytes in breast cancer.
Baxevanis CN; Dedoussis GV; Papadopoulos NG; Missitzis I; Stathopoulos GP; Papamichail M
Cancer; 1994 Aug; 74(4):1275-82. PubMed ID: 7914469
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and Pharmacodynamic Effects of Nemvaleukin Alfa, a Selective Agonist of the Intermediate-Affinity IL-2 Receptor, in Cynomolgus Monkeys.
Lopes JE; Sun L; Flick HL; Murphy EA; Losey HC
J Pharmacol Exp Ther; 2021 Nov; 379(2):203-210. PubMed ID: 34362793
[TBL] [Abstract][Full Text] [Related]
16. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside.
O'Malley BW; Li D; McQuone SJ; Ralston R
Laryngoscope; 2005 Mar; 115(3):391-404. PubMed ID: 15744147
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of anti-PD-1-based therapy against triple-negative breast cancer patient-derived xenograft tumors engrafted in humanized mouse models.
Rosato RR; Dávila-González D; Choi DS; Qian W; Chen W; Kozielski AJ; Wong H; Dave B; Chang JC
Breast Cancer Res; 2018 Sep; 20(1):108. PubMed ID: 30185216
[TBL] [Abstract][Full Text] [Related]
18. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts.
Capasso A; Lang J; Pitts TM; Jordan KR; Lieu CH; Davis SL; Diamond JR; Kopetz S; Barbee J; Peterson J; Freed BM; Yacob BW; Bagby SM; Messersmith WA; Slansky JE; Pelanda R; Eckhardt SG
J Immunother Cancer; 2019 Feb; 7(1):37. PubMed ID: 30736857
[TBL] [Abstract][Full Text] [Related]
19. T cells isolated from patients with checkpoint inhibitor-resistant melanoma are functional and can mediate tumor regression.
Andersen R; Borch TH; Draghi A; Gokuldass A; Rana MAH; Pedersen M; Nielsen M; Kongsted P; Kjeldsen JW; Westergaard MCW; Radic HD; Chamberlain CA; Hölmich LR; Hendel HW; Larsen MS; Met Ö; Svane IM; Donia M
Ann Oncol; 2018 Jul; 29(7):1575-1581. PubMed ID: 29688262
[TBL] [Abstract][Full Text] [Related]
20. Engineering Newcastle Disease Virus as an Oncolytic Vector for Intratumoral Delivery of Immune Checkpoint Inhibitors and Immunocytokines.
Vijayakumar G; McCroskery S; Palese P
J Virol; 2020 Jan; 94(3):. PubMed ID: 31694938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]